Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Warts 2Keratosis, Actinic 2Hyperthermia 2Hematologic Neoplasms 2Hemangioma 2Squamous Intraepithelial Lesions 1Skin Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Pituitary Neoplasms 1Pelvic Neoplasms 1Pain 1Obesity 1Nonmelanoma Skin Cancers 1Mucositis 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Melanoma 1Kidney Neoplasms 1Invasive Fungal Infections 1Insulinoma 1Infertility, Female 1Infertility 1Inappropriate Prescribing 1Hyperinsulinism 1Hemorrhage 1Head and Neck Carcinoma 1

Interventions

Solutions 1Haloperidol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Haloperidol × Solutions × Clear all
NCT04833023 2024-04-12

HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial

Tan Tock Seng Hospital

Phase 3 Unknown
72 enrolled

Haloperidol

Data powered by HemOnc (CC BY 4.0) Colophon âš¡